New research criteria have been developed that define three principal phases in Alzheimers disease: Preclinical, Mild Cognitive Impairment, and dementia.These criteria consider the cognitive and biomarker status of the patient.Biomarkers are divided into two types: Biomarkers of amyloid and biomarkers of neuronal injury.The latter closely parallel progression of clinical symptoms.Magnetoencephalography is an underutilized biomarker of synaptic function that may be useful as a preclinical marker of disease and could also be used to measure effects of therapy.This talk sets the framework for using magnetoencephalography and describes emerging data on its utility in Alzheimers disease.